View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
About one-third of patients taking warfarin (Coumadin) metabolize the drug differently than expected, which can lead to an inadequate therapeutic response or bleeding complications. Responding to recent genetic research, the FDA has approved new labeling that includes information about the impact of genetic information on a patient's response to warfarin. This is an example of the FDA's "personalized medicine" initiative, which draws on scientific findings to tailor drug therapy to an individual's genetic makeup.
In the case of warfarin, research suggests that some unexpected responses to warfarin are tied to variations in two specific genes, CYP2C9 and VKORC1. Patients with these variations can be identified with genetic testing. The new labeling encourages prescribers to use genetic testing to improve their estimate of a reasonable initial dose for a patient taking warfarin. As therapy continues, the prescriber uses International Normalized Ratio monitoring to assess the patient's response.
Following insulin, warfarin is the second most common drug implicated in ED visits for adverse drug reactions. According to the FDA, genetic testing "may optimize the use of warfarin and lower the risk of bleeding complications from the drug."
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top